Levetiracetam in Early Psychosis

  • participants needed
  • sponsor
    NYU Langone Health
Updated on 30 June 2022
cognitive impairment
structured clinical interview
schizoaffective disorder
schizophreniform disorder
affective psychosis
Accepts healthy volunteers


In order to establish target engagement and identify an effective dose the investigators will conduct a placebo-controlled single-dose parallel group trial of levetiracetam 185 mg and 500 mg in 24 medication-nave early psychosis (EP) patients, measuring hippocampal activity by pulsed arterial spin labelling (ASL) pre-dose and 2 hours post-dose. The lower dose is calculated to achieve blood levels within the range that were associated with reduced hippocampal activity and improved cognition in patients with mild cognitive impairment; the higher dose is a typical antiepileptic dose. Successful demonstration of target engagement will be defined by an effect size of 0.5 or greater compared to placebo in reduction by levetiracetam of hippocampal blood flow measured by ASL. The optimal dose will be defined by maximal reduction of hippocampal perfusion in the absence of clinically-significant adverse effects. The investigators will also study 8 healthy control subjects to verify that baseline hippocampal blood flow is elevated in the sample of FEP subjects.

Condition Schizophrenia and Schizoaffective Disorders, Schizophrenia, psychotic, schizoaffective disorder, psychotic disorders, schizophrenia disorders, Schizophrenia and Schizoaffective Disorders (Pediatric), Psychosis, Schizophreniform, psychotic disorder
Treatment Levetiracetam
Clinical Study IdentifierNCT03129360
SponsorNYU Langone Health
Last Modified on30 June 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note